The microbiome and chronic rhinosinusitis

Česká verze

Authors: K. Mamiňák ^1,2 ; D. Funda ³ ; Š. Zavázalová ^1,2 ; T. Filipovský ^1,2 ; D. Kovář ^1,2 ; K. Janoušková ^1,2 ; R. Holý ^1,2 ; J. Astl ^1,2
Authors place of work: Klinika otorinolaryngologie a maxilofaciální chirurgie 3. LF UK a ÚVN Praha ¹; 3. lékařská fakulta, Univerzita Karlova, Praha ²; Laboratoř buněčné a molekulární imunologie, Mikrobiologický ústav Akademie věd ČR, v. v. i. ³
Published in the journal: Otorinolaryngol Foniatr, 73, 2024, No. 3, pp. 182-190.
Category: Přehledová práce
doi: https://doi.org/10.48095/ccorl2024182

Summary

Chronic rhinosinusitis (CRS) is a complex heterogeneous inflammatory disease of the nasal cavity and paranasal sinuses, which very often leads to a decrease in the quality of life with subsequent socioeconomic burden on health services and medical care. CRS is clinically divided into chronic rhinosinusitis with polyps (CRSwNP) and chronic rhinosinusitis without polyps (CRSsNP). Currently, research focuses on the composition of microflora in individual parts of the human body, which has already helped clarify the role of the microbiome in inflammatory respiratory diseases such as bronchial asthma and chronic obstructive pulmonary disease (COPD). Furthemore, research also focuses on the role of the nasal microbiome in possible initiation and potentiation of CRS. A healthy nasal microbiological environment is composed of bacteria, fungi, and viruses. A closer understanding of interactions between microbes and individual components of the immune system may help clarify the pathophysiological mechanisms involved during CRS. In this review article, we will focus on the current knowledge of composition changes and the possible role of the complex microbiome of the upper respiratory tract in CRS compared to a healthy nasal environment.

Keywords:

mucosal immunity – chronic rhinosinusitis – Microbiome – probiotics – chronic inflammation

Zdroje

1. Marchesi JR, Ravel J. The vocabulary of microbiome research: a proposal. Microbiome 2015; 3: 31. Doi: 10.1186/s40168-015-0094-5.

2. Černý V, Hrdý J, Beneš Jet al. A word on the microbiome: considerations about the history, current state, and terminology of an emerging discipline. Epidemiol Mikrobiol Imunol 2023; 72 (2): 112–118.

3. Casadevall A, Pirofski LA. What is a host? Incorporating the microbiota into the damage-response framework. Infect Immun 2015; 83 (1): 2–7. Doi: 10.1128/IAI.02627-14.

4. Watts AM, West NP, Zhang P et al. The Gut Microbiome of Adults with Allergic Rhinitis Is Characterised by Reduced Diversity and an Altered Abundance of Key Microbial Taxa Compared to Controls. Int Arch Allergy Immunol 2021; 182 (2): 94–105. Doi: 10.1159/000510536.

5. Mazmanian SK, Liu CH, Tzianabos AO et al. An immunomodulatory molecule of symbiotic bacteria directs maturation of the host immune system. Cell 2005; 122 (1): 107–118. Doi: 10.1016/ j.cell.2005.05.007.

6. Round JL, Mazmanian SK. The gut microbiota shapes intestinal immune responses during health and disease. Nat Rev Immunol 2009; 9 (5): 313–323. Doi: 10.1038/nri2515.

7. Fokkens WJ, Lund VJ, Mullol J et al. EPOS 2012: European position paper on rhinosinusitis and nasal polyps 2012. A summary for otorhinolaryngologists. Rhinology 2012; 50 (1): 1–12. Doi: 10.4193/Rhino12.000.

8. Chang L, Wu H, Huang W et al. IL-21 induces pyroptosis of Treg cells via Akt-mTOR-NLRP3-caspase 1 axis in eosinophilic chronic rhinosinusitis. J Allergy Clin Immunol 2023; 152 (3): 641.e14–655.e14. Doi: 10.1016/j.jaci.2023.04.013.

9. Kondělková K, Vokurková D, Krejsek J et al. Regulatory T cells (TREG) and their roles in immune system with respect to immunopathological disorders. Acta Medica (Hradec Kralove) 2010; 53 (2): 73–77. Doi: 10.14712/18059694.2016.63.

10. Dietz de Loos D, Lourijsen ES, Wildeman MAM et al. Prevalence of chronic rhinosinusitis in the general population based on sinus radiology and symptomatology. J Allergy Clin Immunol 2019; 143 (3): 1207–1214. Doi: 10.1016/j.jaci.2018.12.986.

11. van Drunen CM, Mjosberg JM, Segboer CL et al. Role of innate immunity in the pathogenesis of chronic rhinosinusitis: progress and new avenues. Curr Allergy Asthma Rep 2012; 12 (2): 120–126. Doi: 10.1007/s11882-012-0249-4.

12. Kato A. Immunopathology of chronic rhinosinusitis. Allergol Int 2015; 64 (2): 121–130. Doi: 10.1016/j.alit.2014.12.006.

13. Paju S, Bernstein JM, Haase EM et al. Molecular analysis of bacterial flora associated with chronically inflamed maxillary sinuses. J Med Microbiol 2003; 52 (Pt 7): 591–597. Doi: 10.1099/jmm.0.05062-0.

14. Hagner S, Harb H, Zhao M et al. Farm-derived Gram-positive bacterium Staphylococcus sciuri W620 prevents asthma phenotype in HDM – and OVA-exposed mice. Allergy 2013; 68 (3): 322–329. Doi: 10.1111/all.12094.

15. Vogel K, Blumer N, Korthals M et al. Animal shed Bacillus licheniformis spores possess allergy-protective as well as inflammatory properties. J Allergy Clin Immunol 2008; 122 (2): 307. e1–e8–312.e1–e8. Doi: 10.1016/j.jaci.2008.05.016.

16. Bassis CM, Tang AL, Young VB et al. The nasal cavity microbiota of healthy adults. Microbiome 2014; 2: 27. Doi: 10.1186/2049-2618-2-27.

17. Anderson M, Stokken J, Sanford T et al. A systematic review of the sinonasal microbiome in chronic rhinosinusitis. Am J Rhinol Allergy 2016; 30 (3): 161–166. Doi: 10.2500/ajra.2016.30.4320.

18. Liang G, Bushman FD. The human virome: assembly, composition and host interactions. Nat Rev Microbiol 2021; 19 (8): 514–527. Doi: 10.1038/s41579-021-00536-5.

19. Blum HE. The human microbiome. Adv Med Sci 2017; 62 (2): 414–420. Doi: 10.1016/ j.advms.2017.04.005.

20. Kumpitsch C, Koskinen K, Schopf V et al. The microbiome of the upper respiratory tract in health and disease. BMC Biol 2019; 17 (1): 87. Doi: 10.1186/s12915-019-0703-z.

21. Wagner Mackenzie B, Chang K, Zoing M et al. Longitudinal study of the bacterial and fungal microbiota in the human sinuses reveals seasonal and annual changes in diversity. Sci Rep 2019; 9 (1): 17416. Doi: 10.1038/s41598-019-53975-9.

22. Wylie KM. The Virome of the Human Respiratory Tract. Clin Chest Med 2017; 38 (1): 11–19. Doi: 10.1016/j.ccm.2016.11.001.

23. Kellam P, Weiss RA. Infectogenomics: insights from the host genome into infectious diseases. Cell 2006; 124 (4): 695–697. Doi: 10.1016/ j.cell.2006.02.003.

24. Nibali L, Henderson B, Sadiq ST et al. Genetic dysbiosis: the role of microbial insults in chronic inflammatory diseases. J Oral Microbiol 2014; 6. Doi: 10.3402/jom.v6.22962.

25. Hsu J, Avila PC, Kern RC et al. Genetics of chronic rhinosinusitis: state of the field and directions forward. J Allergy Clin Immunol 2013; 131 (4): 977e.1–e5–993 e.1–e5. Doi: 10.1016/ j.jaci.2013.01.028.

26. Fundova P, Filipovsky T, Funda DP et al. Expression of IGF-1R and iNOS in nasal polyps; epithelial cell homeostasis and innate immune mechanisms in pathogenesis of nasal polyposis. Folia Microbiol (Praha) 2008; 53 (6): 558–562. Doi: 10.1007/s12223-008-0089-8.

27. Brown CA, Paisner HM, Biel MA et al. Evaluation of the Microbiology of Chronic Maxillary Sinusitis. Ann Otol Rhinol Laryngol 1998; 107 (11): 942–945. Doi: 10.1177/000348949810701107.

28. Wei HZ, Li YC, Wang XD et al. The microbiology of chronic rhinosinusitis with and without nasal polyps. Eur Arch Otorhinolaryngol 2018; 275 (6): 1439–1447. Doi: 10.1007/s00405-018-4931-4936.

29. Stressmann FA, Rogers GB, Chan SW et al. Characterization of bacterial community diversity in chronic rhinosinusitis infections using novel culture-independent techniques. Am J Rhinol Allergy 2011; 25 (4): e133–e140. Doi: 10.2500/ajra.2011.25.3628.

30. Feazel LM, Robertson CE, Ramakrishnan VR et al. Microbiome complexity and Staphylococcus aureus in chronic rhinosinusitis. Laryngoscope 2012; 122 (2): 467–472. Doi: 10.1002/lary.22398.

31. Aurora R, Chatterjee D, Hentzleman J et al. Contrasting the microbiomes from healthy volunteers and patients with chronic rhinosinusitis. JAMA Otolaryngol Head Neck Surg 2013; 139 (12): 1328–1338. Doi: 10.1001/jamaoto.2013.5465.

32. Choi EB, Hong SW, Kim DK et al. Decreased diversity of nasal microbiota and their secreted extracellular vesicles in patients with chronic rhinosinusitis based on a metagenomic analysis. Allergy 2014; 69 (4): 517–526. Doi: 10.1111/all.12374.

33. Abreu NA, Nagalingam NA, Song Y et al. Sinus microbiome diversity depletion and Corynebacterium tuberculostearicum enrichment mediates rhinosinusitis. Sci Transl Med 2012; 4 (151): 151ra124. Doi: 10.1126/scitranslmed.3003783.

34. Cope EK, Goldberg AN, Pletcher SD et al. Compositionally and functionally distinct sinus microbiota in chronic rhinosinusitis patients have immunological and clinically divergent consequences. Microbiome 2017; 5 (1): 53. Doi: 10.1186/s40168-017-0266-6.

35. Gan W, Zhang H, Yang F et al. The influence of nasal microbiome diversity and inflammatory patterns on the prognosis of nasal polyps. Sci Rep 2021; 11 (1): 6364. Doi: 10.1038/s41598-021-85292-5.

36. Cho GS, Moon BJ, Lee BJ et al. High rates of detection of respiratory viruses in the nasal washes and mucosae of patients with chronic rhinosinusitis. J Clin Microbiol 2013; 51 (3): 979–984. Doi: 10.1128/JCM.02806-12.

37. Liao B, Hu CY, Liu T et al. Respiratory viral infection in the chronic persistent phase of chronic rhinosinusitis. Laryngoscope 2014; 124 (4): 832–837. Doi: 10.1002/lary.24348.

38. Goggin RK, Bennett CA, Bialasiewicz S et al. The presence of virus significantly associates with chronic rhinosinusitis disease severity. Allergy 2019; 74 (8): 1569–1572. Doi: 10.1111/all.13772.

39. Wu X, Peters-Hall JR, Ghimbovschi S et al. Glandular gene expression of sinus mucosa in chronic rhinosinusitis with and without cystic fibrosis. Am J Respir Cell Mol Biol 2011; 45 (3): 525–533. Doi: 10.1165/rcmb.2010-0133OC.

40. Schleimer RP, Kato A, Kern R et al. Epithelium: at the interface of innate and adaptive immune responses. J Allergy Clin Immunol 2007; 120 (6): 1279–1284. Doi: 10.1016/j.jaci.2007.08.046.

41. Ramanathan M, Jr., Lee WK, Spannhake EW et al. Th2 cytokines associated with chronic rhinosinusitis with polyps down-regulate the antimicrobial immune function of human sinonasal epithelial cells. Am J Rhinol 2008; 22 (2): 115–121. Doi: 10.2500/ajr.2008.22.3136.

42. Mahdavinia M, Keshavarzian A, Tobin MC et al. A comprehensive review of the nasal microbiome in chronic rhinosinusitis (CRS). Clin Exp Allergy 2016; 46 (1): 21–41. Doi: 10.1111/cea.12666.

43. Hatakeyama M. Helicobacter pylori and gastric carcinogenesis. J Gastroenterol 2009; 44 (4): 239–248. Doi: 10.1007/s00535-009-0014-1

44. Kabelka Z, Kolešková D, Krylová Z et al. Účinky laktoflóry podané intranazálně, výsledky primární studie. Otorinolaryngol Foniatr 2014; 63 (3): 182–186.

45. Huntley KS, Raber J, Fine L et al. Influence of the Microbiome on Chronic Rhinosinusitis With and Without Polyps: An Evolving Discussion. Front Allergy 2021; 2: 737086. Doi: 10.3389/falgy.2021.737086.

46. Chong LY, Head K, Hopkins C et al. Saline irrigation for chronic rhinosinusitis. Cochrane Database Syst Rev 2016; 4 (4): CD011995. Doi: 10.1002/14651858.CD011995.pub2.

47. Chong LY, Head K, Hopkins C et al. Intranasal steroids versus placebo or no intervention for chronic rhinosinusitis. Cochrane Database Syst Rev 2016; 4 (4): CD011996. Doi: 10.1002/14651858.CD011996.pub2.

48. Khalil HS, Nunez DA. Functional endoscopic sinus surgery for chronic rhinosinusitis. Cochrane Database Syst Rev 2006; 3: CD004458. Doi: 10.1002/14651858.CD004458.pub2.

49. Hoy SM. Dupilumab: A Review in Chronic Rhinosinusitis with Nasal Polyps. Drugs 2020; 80 (7): 711–717. Doi: 10.1007/s40265-020-01298-9.

50. Cope EK, Lynch SV. Novel microbiome-based therapeutics for chronic rhinosinusitis. Curr Allergy Asthma Rep 2015; 15 (3): 504. Doi: 10.1007/s11882-014-0504-y.

51. Cho DY, Hunter RC, Ramakrishnan VR. The Microbiome and Chronic Rhinosinusitis. Immunol Allergy Clin North Am 2020; 40 (2): 251–263. Doi: 10.1016/j.iac.2019.12.009.

52. Mukerji SS, Pynnonen MA, Kim HM et al. Probiotics as adjunctive treatment for chronic rhinosinusitis: a randomized controlled trial. Otolaryngol Head Neck Surg 2009; 140 (2): 202–208. Doi: 10.1016/j.otohns.2008.11.020.

53. Cervin AU. The Potential for Topical Probiotic Treatment of Chronic Rhinosinusitis, a Personal Perspective. Front Cell Infect Microbiol 2017; 7: 530. Doi: 10.3389/fcimb.2017.00530.

54. Ba L, Zhang N, Meng J et al. The association between bacterial colonization and inflammatory pattern in Chinese chronic rhinosinusitis patients with nasal polyps. Allergy 2011; 66 (10): 1296–1303. Doi: 10.1111/j.1398-9995.2011.02637.x.

55. Ahmed N, Mahmoud NF, Solyman S et al. Human Nasal Microbiome as Characterized by Metagenomics Differs Markedly Between Rural and Industrial Communities in Egypt. OMICS 2019; 23 (11): 573–582. Doi: 10.1089/omi.2019.0144.

56. Jiang RS, Su MC, Lin JF. Nasal mycology of chronic rhinosinusitis. Am J Rhinol 2005; 19 (2): 131–133. Doi: 10.1177/194589240501900204.

57. Renteria AE, Mfuna Endam L, Desrosiers M. Do Aging Factors Influence the Clinical Presentation and Management of Chronic Rhinosinusitis? Otolaryngol Head Neck Surg 2017; 156 (4): 598–605. Doi: 10.1177/0194599817691258.

ORCID autorů

K. Mamiňák 0000-0002-3935-5891,

D. Funda 0000-0001-8327-6931,

Š. Zavázalová 0000-0002-2710-119X,

T. Filipovský 0000-0002-9462-0635,

K. Janoušková 0000-0003-3939-7538,

R. Holý 0000-0003-1112-6197,

J. Astl 0000-0002-8022-0200.

Přijato k recenzi: 3. 8. 2023

Přijato k tisku: 13. 11. 2023

MUDr. Kristýna Mamiňák

Klinika otorhinolaryngologie a maxilofaciální chirurgie